 |
answer text |
<p>UKRI is currently funding one study of direct relevance to these areas. UKRI has
allocated an initial £1.8 million to the OCTAVE study, led by Professor Iain McInnes,
University of Glasgow, for a twelve-month period, and is considering a case for additional
funding beyond this. OCTAVE is supporting research on vaccine responses in groups
of immune-supressed individuals, including those with inflammatory disorders, high
risk cancer patient groups, and patients with severe kidney and liver disease. Cancer
patient groups include chronic lymphocytic leukaemia, myeloma, acute leukaemia, and
bone marrow transplants. As the OCTAVE study is being managed as a single project
it is not possible to give costs for the individual groups.</p><p> </p><p>In addition,
there are proposals on vaccine responses in high-risk clinical groups under consideration
as part of the UKRI COVID-19 Agile call, with announcements to be made shortly. Furthermore,
UKRI continues to accept applications for COVID-19 related research, including on
this topic, through its active calls, which can be found on the UKRI website.</p>
|
|
